Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors
Year: 2025
Type: article
Study design: Observational Study
Abstract: A comparative analysis of Denosumab (DMAB) and Zoledronic Acid (ZA) was conducted in a real-world cohort of 864 patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with bone metastases, who were undergoing CDK4/6 inhibitors plus endocrine therapy. We evaluated the time to first skeletal-related events (SREs), progression-free survival (PFS), and overall survival (OS). To adjust for confounding variables, we utilized propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) methodologies. In the unadjusted cohort, ZA was associated with a longer time to first SRE compared to DMAB (HR = 0.77, 95 % CI: 0.61-0.98, p = 0.031). Similar results were obtained in both the PSM (HR = 0.69, 95 % CI: 0.52-0.92, p = 0.011) and IPTW cohorts (HR = 0.74, 95 % CI: 0.63-0.87, p < 0.001), with ZA-treated patients showing an extended time to first SRE compared to those treated with DMAB. No differences in PFS and OS were observed between the two cohorts.
Source: The Breast
Authors: Roberta Scafetta, Marco Donato, Carla Gullotta, Alessandra Guarino, Cristina Fiore, Luisana Sisca, Elena Speziale, Raffaella Troiano, Simone Foderaro, Valentina Ricozzi, Michele Iuliani, Sonia Simonetti, Silvia Cavaliere, Alessio Cortellini, Andrea Botticelli, Simone Scagnoli, Simona Pisegna, Carmen Criscitiello, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D'Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Maria Grazia Rossino, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Edy Ippolito, Sara Ramella, Luca Visani, Niccolò Bertini, Ilaria Bonaparte, Stefania Gori, Luigi Rossi, Icro Meattini, Barbara Tagliaferri, Orazio Caffo, Ilaria Portarena, Azzurra Irelli, Elisabetta Cretella, Camillo Porta, Giampaolo Bianchini, Agnese Fabbri, Ugo De Giorgi, Patrizia Vici, Angela Toss, Ornella Garrone, Michelino De Laurentiis, Federica Villa, Rossana Berardi, Mauro Minelli, Claudio Vernieri, Giuseppe Curigliano, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Francesco Pantano
Institutions: Università Campus Bio-Medico, Campus Bio Medico University Hospital, Ospedale di Belcolle, Policlinico Umberto I, Sapienza University of Rome, University of Milan, European Institute of Oncology, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Fondazione IRCCS Istituto Nazionale dei Tumori, Marche Polytechnic University, Ospedale Sandro Pertini, Istituti di Ricovero e Cura a Carattere Scientifico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Azienda Ospedaliero-Universitaria di Modena, Instituto Nazionale Tumori Regina Elena, Istituti Clinici Scientifici Maugeri, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS Ospedale San Raffaele, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Ospedale Santa Chiara, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Ospedale Sacro Cuore Don Calabria, University of Rome Tor Vergata, Policlinico Tor Vergata, Ospedale di Bolzano, Vita-Salute San Raffaele University, Aziende Socio Sanitarie Territoriali di Lecco, Azienda Ospedaliera San Giovanni Addolorata
Language: English
Topic: Bone health and treatments
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,200
OpenAlex ID: W4410383175